Insider Selling: Aerie Pharmaceuticals major shareholder Sells 300,000 Shares of Stock (AERI)
Aerie Pharmaceuticals (NASDAQ:AERI) major shareholder Iv L.P. Acp sold 300,000 shares of the stock on the open market in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $16.00, for a total value of $4,800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Aerie Pharmaceuticals (NASDAQ:AERI) traded down 1.19% on Tuesday, hitting $15.76. The stock had a trading volume of 45,375 shares. Aerie Pharmaceuticals has a 1-year low of $10.25 and a 1-year high of $27.149. The stock has a 50-day moving average of $15.90 and a 200-day moving average of $17.23. The company’s market cap is $369.4 million.
Aerie Pharmaceuticals (NASDAQ:AERI) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. Analysts expect that Aerie Pharmaceuticals will post $-1.48 EPS for the current fiscal year.
A number of analysts have recently weighed in on AERI shares. Analysts at RBC Capital cut their price target on shares of Aerie Pharmaceuticals from $28.00 to $27.00 in a research note on Tuesday, May 13th. They now have an “outperform” rating on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Aerie Pharmaceuticals from $22.00 to $24.00 in a research note on Wednesday, March 19th. They now have a “buy” rating on the stock.
Aerie Pharmaceuticals, Inc is a United States-based company. The Company is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.